Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

T-cell-prolymphocytic Leukemia
Cutaneous T-Cell Lymphoma Refractory

Interventions

DRUG: Duvelisib
DRUG: Venetoclax

Sponsor

Jonsson Comprehensive Cancer Center